GlassScriptPhysician profile
Lisa Shaffer
NPI 1487364949
$2,124.47
in general payments reported to CMS, 2019-2025
29 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $214 · 2024: $1,122 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.88 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $228.58 | 2024 | Breztri, Farxiga |
| Inspire Medical Systems, INC. | $149.51 | 2025 | Inspire |
| Novo Nordisk INC | $131.02 | 2023-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $121.83 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $91.63 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.54 | 2023-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $67.40 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $46.52 | 2024 | Aptima |
| Almatica Pharma LLC | $46.24 | 2025 | Loreev Xr |
| Dexcom, INC. | $42.63 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $42.12 | 2024 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $41.79 | 2024 | |
| Cleerly, INC. | $35.70 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Takeda Pharmaceuticals U.S.A., INC. | $33.55 | 2024 | Eohilia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.69 | 2024-2025 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.02 | 2025 | Xifaxan |
| Viatris Specialty LLC | $29.37 | 2025 | Yupelri |
| Ardelyx, INC. | $25.01 | 2024 | Ibsrela |
| Medtronic, INC. | $23.90 | 2024 | Intellis Adaptivestim |
| Pfizer INC. | $23.14 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.56 | 2024 | Voquezna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.65 | 2025 | Lifevest |
| Exact Sciences Corporation | $17.44 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $17.24 | 2023 | Korlym |
| Janssen Biotech, INC. | $16.65 | 2024 | Stelara |
| Braintree Laboratories, INC. | $14.52 | 2024 | Suflave |
| Abiomed | $13.70 | 2023 | Impella |
| Advanced Oxygen Therapy INC. | $6.64 | 2025 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.